35 results about "Dose drugs" patented technology

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR12 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR12 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR12 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR12 has high affinity and dilution stability and is suitable for clinical large-dose administration.

The infusion packaging system with the medicine mixing function comprises an infusion container, and a combined cover structure with the medicine mixing function is connected to an opening of the infusion container in a sealed mode. The combined cover structure with the medicine mixing function comprises a protective sleeve, a puncture needle with the medicine mixing function and a combined cover. The protective sleeve is provided with an easy-to-tear line structure used for removing the protective sleeve in a segmented mode. The combined cover comprises an inner cover, the outer side of the inner cover is hermetically buckled with an outer cover, a sealing cavity is formed between the top end of the inner cover and the top end of the outer cover, and a sealing gasket is arranged in the sealing cavity; the puncture needle is arranged in the protective sleeve in a sliding mode. A combined cover structure with a medicine mixing function is adopted, and the combined cover can be welded with an infusion container into a whole to form a packaging system which is reliable in sealing. The sealing can effectively ensure that the puncture needle in the protective sleeve and the exposed area of the sealing gasket are prevented from being polluted by the outside in high-temperature steam sterilization and subsequent storage and transportation in the large-delivery medicine production process, and the safety of medicine use is ensured.

The present invention belongs to the technical field of anorectal treatment, and particularly relates to a stacked anal nozzle for anal hemostasis and drug administration, which comprises an inner nozzle body and an outer nozzle body. The inner nozzle body is arranged inside the outer nozzle body, and a drug cavity is formed between the two. A plurality of drug holes are provided on the outer nozzle body. Through the drug holes, the drugs in the drug cavity can reach the lesion site. An insertion part conforming to the shape of the anus is provided on the outer nozzle body. First exhaust holes are correspondingly provided on the inner nozzle body and the outer nozzle body. A cap is provided at the end of the insertion part, and a second exhaust hole is provided on the cap. The first exhaust hole is communicated with the second exhaust hole. An airbag is provided on the outer edge of the cap, and the airbag is connected with an inflation tube. The present invention can ensure the single-dose drug administration, prolong the action time, has a good fitting effect between the drug and the lesion, the drug is in direct contact with the lesion, has a good action effect, remarkable curative effect, and does not affect the exhaust; it can perform hemostasis care without affecting drug administration and drug absorption, which is beneficial to shortening the treatment process and improving the treatment effect.

Provided is use of a compound represented by Formula (I), or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I) in the manufacture of a medicament for treating and / or preventing an immune system disease.

The utility model provides a single medicine discharging bottle. The single medicine outlet bottle comprises a bottle body; the external threaded pipe is fixedly connected to the top end of the bottle body, and the outer surface of the external threaded pipe is in threaded connection with a bottle cap; the medicine taking tube is fixedly connected to the top end of the bottle cap, a medicine inlet is formed in the position, located at the bottom end, of the outer surface of the medicine taking tube, a rotating tube is arranged in the medicine taking tube, a medicine outlet is formed in the position, located at the bottom end, of the outer surface of the rotating tube, and a rotating disc is fixedly connected to the top end of the rotating tube. A rotating buckle is installed on the outer surface of the rotating disc, and a sealing cover is installed at the top end of the rotating disc through a rotating head. According to the single-grain medicine discharging bottle, single-grain medicine taking of the medicine bottle can be achieved each time through the structure, the probability that the medicine bottle is exposed outside and makes contact with external objects is reduced, the probability that medicine grains in the medicine bottle are polluted is reduced, and single-grain medicine taking of the medicine bottle is facilitated.

The utility model relates to a combined cover structure for an infusion container with a medicine mixing function. The combined cover structure comprises a protective sleeve, a puncture needle with the medicine mixing function and a combined cover, the first end of the protective sleeve is closed, the second end of the protective sleeve is open, the second end of the protective sleeve is buckled on the outer side of the combined cover, and an easy-to-tear line structure is arranged on the protective sleeve; the combined cover comprises an inner cover, an outer cover is buckled on the outer side of the inner cover, a sealing cavity is formed between the inner cover and the outer cover, and a sealing gasket is arranged in the sealing cavity; the puncture needle is arranged in the protective sleeve in a sliding mode and comprises a first tip and a second tip, and a channel hole is formed in the puncture needle in a penetrating mode. According to the utility model, the protective sleeve adopts an integrated structure with an easy-to-tear line structure, and the protective sleeve and the combined cover are assembled into a whole; it is effectively guaranteed that the puncture needle with the medicine mixing function in the protection sleeve and the exposed area of the sealing gasket are prevented from being polluted by the outside in the high-temperature steam sterilization in the large-infusion medicine production process and the subsequent storage and transportation process, and the safety of medicine use is guaranteed.

The invention relates to a preparation method and application of a hydrogel microneedle loaded with a glutathione storage cavery.The preparation method aims at achieving more efficient drug delivery, and according to the technical scheme, the preparation method specifically comprises the following steps that 1, a PDMS microneedle female template is prepared; 2) preparing a hydrogel microneedle material solution; 3) preparing a blank hydrogel microneedle; (4) preparing a hydrogel microneedle loaded with a glutathione storage cavern; the hydrogel microneedle loaded with the glutathione reservoir integrates the advantages of the hydrogel microneedle and the drug reservoir, the hydrogel microneedle can form a tiny channel on the skin surface, percutaneous delivery of drugs is promoted, the drug delivery efficiency is improved, the drug reservoir is carried, and the drug delivery efficiency is improved. The hydrogel microneedle has the advantages that glutathione can be prevented from being degraded due to high-temperature crosslinking and the like in the preparation process of the microneedle, the hydrogel microneedle and the glutathione reservoir are jointly applied, limitation of limited space of a microneedle body is broken through, continuous large-dose administration is realized, and the hydrogel microneedle has high percutaneous delivery efficiency.

The invention belongs to the technical field of neurobiology, and particularly relates to application of a dopamine D2 receptor G protein antagonist in preparation of a drug for treating drug addiction. Researches show that the dopamine D2 receptor G protein antagonist can inhibit recurrence after drug addiction fading induced by ignition of small-dose drugs. A mouse cocaine self-administration addiction model is adopted, a small dose of cocaine is given after model mice are subjected to regression training, and the recurrence behavior of the mouse cocaine addiction after regression is induced. A signal channel dependent on dopamine D2 receptor downstream G protein is inhibited before addiction recurrence is induced by a small dose of cocaine, and recurrence after drug-induced cocaine fading can be inhibited; however, the signal pathway for inhibiting the dependence of beta-arretin on the downstream of the dopamine D2 receptor cannot inhibit the recurrence after drug-induced cocaine fading. The invention discloses the effect of the G protein biased antagonist of the dopamine D2 receptor in treatment of drug addiction, and provides a new thought and a drug intervention target for treatment of drug addiction of cocaine and the like.

The invention belongs to the technical field of medicines, and particularly relates to a high-efficiency low-toxicity anticancer combined medicine and a pharmaceutical composition. The invention provides application of guanidine compounds combined with piperlongumine in preparation of anti-cancer drugs. Wherein the guanidine compound can be selected from metformin. Compared with a single-dose drug, the combined drug provided by the invention has better anticancer activity. Compared with platinum chemotherapeutic drugs, the drug combination scheme has the same tumor killing efficacy, and has no obvious influence on mouse weight, immune system, liver function, kidney function and the like, which indicates that the toxic and side effects of the drug combination are obviously weaker than those of the platinum chemotherapeutic drugs. Therefore, the drug combination scheme provided by the invention has a very good application prospect.

To provide improved methods, devices, and systems to provide multi-dose injection regimens without risking contamination of a therapeutic agent disposed within a reusable injector.SOLUTION: Systems and devices include multi-dose injection systems for delivering drugs, hormones, biologics, and other therapeutic agents. The systems include multiple single-injection needle connectors 102 attachable to a reusable injector. The needle connectors include a needle 104 having a distal end 106 for administering a therapeutic agent to a patient and a proximal end 108 to pierce a septum of the reusable injector. Proximal ends of the needles across the multiple needle connectors can be varied such that a piercing location on the septum varies.SELECTED DRAWING: Figure 1

The invention discloses a disassembled medicine dispensing box for an automatic medicine dispensing machine based on triggering opening of a code scanning gun, and relates to the field of automatic medicine dispensing machines, the disassembled medicine dispensing box comprises a box body with one end provided with an opening, the bottom of the box body is rotatably connected with a box cover used for sealing the opening of the box body, and a storage box used for storing disassembled medicines is arranged in the box body; a sealing cover used for sealing the storage box is fixedly connected to the box cover, and the supporting plate is connected to the interior of the storage box in a sliding mode and can stretch out of the box body in the opening direction of the box body. According to the medicine box, the sealing performance of the storage position of the disassembled medicine is effectively guaranteed, then the storage quality of the medicine is guaranteed, meanwhile, when the box body is opened, the supporting plate automatically slides out, a pharmacist can conveniently take away the medicine on the supporting plate, medicine traceability code management is implemented nationwide, the pharmacist opens the medicine box while scanning traceability codes, and the medicine box is convenient to use. The work flow is simplified, the comprehensive implementation of the drug traceability code is promoted, and the drug traceability code management is standardized.

A machine learning system can predict a therapeutic effect of a compound when administered to humans. The machine learning system can obtain multiple observational datasets acquired during trials in which a non-human animal was administered varying dosages of the compound. The machine learning system can apply the multiple observational datasets to a machine learning model trained to predict, based on such observational datasets, therapeutic effect(s) of the compound when administered to humans. The machine learning model can include multiple encoders, each encoder corresponding to a dosage level. The machine learning model can further include a classifier configured to generate indication(s) of therapeutic class(es) using the outputs of the encoders.

The invention concerns improvements in needle-free devices for delivery of therapeutic and / or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free device disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and / or patient.

The invention provides a low-dose transdermal patch with high drug release, and relates to the technical field of transdermal patches. The low-dose transdermal patch with high drug release comprises a backing layer, an intelligent response type pressure-sensitive adhesive storage layer and an anti-sticking layer, and the intelligent response type pressure-sensitive adhesive storage layer is composed of an upper quick release adjusting layer, a middle buffer transition layer and a lower slow release core layer; the upper quick-release adjusting layer contains a temperature-sensitive penetration promoting system and is composed of composite microspheres of menthol, borneol and polyoxyethylated castor oil, the surfaces of the composite microspheres are coated with poly (N-isopropylacrylamide) temperature-sensitive coatings, when the skin temperature is higher than 34 DEG C, the coatings swell to accelerate drug release, and the content of the coatings accounts for 5%-20% (w / w) of the total weight of the upper layer. And through an intelligent response mechanism, the low-dose drug effect is improved, the stimulation is reduced, various environments are adapted, the targeting property is enhanced, and the medication safety and applicability are improved.

The invention belongs to the technical field of dosing instruments, and discloses an equal-dose injection device matched with a robot for use, an injector is provided with a liquid inlet cavity, a liquid outlet cavity and a variable-pressure cavity, one end of the liquid inlet cavity is connected with a liquid storage bottle, one end of the liquid outlet cavity is communicated with the liquid inlet cavity, the other end of the liquid outlet cavity is provided with an injection needle, one end of the variable-pressure cavity is communicated with the liquid inlet cavity, and the other end of the variable-pressure cavity is provided with a variable-pressure module; the variable-pressure module conducts pressure reduction motion and pressure increasing motion on the variable-pressure cavity in a crossed mode, liquid in the liquid storage bottle enters the liquid inlet cavity when the liquid inlet cavity is in the negative pressure state, the liquid enters the liquid inlet cavity and is pushed into the injection needle when the liquid inlet cavity is in the positive pressure state, the frequency of the pressure reduction motion and the frequency of the pressure increasing motion are fixed, and in each circulation of the pressure reduction motion and the pressure increasing motion, the injection needle is pushed into the injection needle. The unit liquid medicine doses pushed into a patient are the same, the number of cycles of injection each time is controlled, injection of the same dose of liquid medicine is achieved in the treatment process, the quick connection module is connected to the voltage transformation module, and the quick connection module is detachably connected with the mechanical arm so that quick connection or separation between the quick connection module and the mechanical arm can be achieved.

The invention concerns improvements in needle-free devices for the delivery of therapeutic and / or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free devices disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and / or patient.

This invention provides an atomization module for an atomizer, comprising a pressure-resistant solution chamber, a pressure assembly, a heating assembly, and a sealing nozzle. The pressure assembly is connected to the pressure-resistant solution chamber and can increase the pressure inside the chamber. The sealing nozzle is connected to an outlet on the pressure-resistant solution chamber and includes a transition section and a spray plate. The spray plate has an internally closed blind hole. The transition section, the blind hole, and the outlet are interconnected. The blind hole opens from the inside out after exceeding the pressure limit, and the liquid to be atomized is sprayed out from the blind hole. The inner diameters of the pressure-resistant solution chamber, the transition section, and the blind hole decrease sequentially. The heating assembly can heat the pressure-resistant solution chamber. The atomization module of this invention has a faster atomization rate, a larger capacity range for atomized solution per spray, and no special requirements on the device posture during atomization. It can deliver both micro-dose and large-dose drugs as needed, making it more widely applicable.

The invention discloses a method for establishing a mouse acute hepatic failure model based on short-term fasting and small-dose PloyI: C / D-GalN induction, and the mouse acute hepatic failure model can be successfully established only by providing 24-hour fasting for a 5-6w c57BL / 6J mouse, then injecting 0.014 [mu] g / g of PloyI: C drug into the tail vein of the mouse and injecting 0.56 mg / g of D-GalN drug into the intraperitoneal cavity of the mouse. Through short-term fasting pretreatment, physiological adjustment of an organism in a stress state is simulated, so that subsequent small-dose PloyI: C / D-GalN induced liver injury is closer to the physiological process of actual disease occurrence and development. Compared with traditional single large-dose drug induction, the method has the advantages that non-characteristic damage caused by excessive drugs is reduced, and the stability and repeatability of the model are improved. The method is simple to operate, special equipment is not needed, and the experiment cost is reduced due to the fact that the dosage of the medicine is reduced.

The invention discloses a sitagliptin phosphate pharmaceutical composition as well as a preparation, a preparation method and application thereof. The pharmaceutical composition comprises sitagliptin phosphate, HP-beta-CD and mesoporous silica. According to the invention, a synergistic effect is generated by utilizing a molecular-level clathration effect of HP-beta-CD and a nano-level confinement adsorption effect of mesoporous silica, so that chemical degradation of sitagliptin phosphate, especially generation of a genotoxic impurity NTTP, is remarkably inhibited from molecular and physical double levels, and the stability of a product is greatly improved. Meanwhile, the mesoporous silica effectively solves the technical problems that HP-beta-CD is strong in hygroscopicity and not easy to directly tablet, and the content uniformity of low-dose drugs is fundamentally ensured by forming uniform composite particles. The process is simple, granulation is not needed, the tablet is suitable for industrial production, the prepared tablet is excellent in stability and high in safety, and animal experiments show that the bioavailability of the tablet is superior to that of a commercially available reference preparation.

The invention discloses preparation of a mesoporous drug-loading system with a controllable aperture and application of the mesoporous drug-loading system in improvement of oral absorption of insoluble drugs, and belongs to the technical field of medicines. The drug loading system takes dendritic mesoporous silica as a carrier of an insoluble drug and fenofibrate as a model drug, is used for improving the physical stability and oral bioavailability of the insoluble drug, and is particularly suitable for clinical large-dose drugs. The dendritic mesoporous silica drug-loading system provided by the invention is superior to commercially available mesoporous auxiliary materials and traditional solid dispersion carrier materials in the aspects of improving the physical stability of the insoluble drug and enhancing the oral absorption effect, and provides important reference for the research of an oral preparation of the insoluble drug.

The invention concerns improvements in needle-free devices for delivery of therapeutic and / or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free device disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and / or patient.

The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal-only dosing of insulin. In a primary embodiment, the wearable drug delivery device is configured to provide automatic operation and provides audible alerts and visual status indicators to the patient. In other embodiments, the patient may have some degree of control over the operation of the device by providing tapping gestures on housing of the device. In yet another embodiment, the patient may provide input and receive status from the device via an application executing on a portable computing device in wireless communication with the wearable drug delivery device.

The invention relates to the technical field of pharmaceutical preparations, and discloses a microneedle patch as well as a preparation method and application thereof. The microneedle comprises a substrate and a needle head, the needle head comprises a cavity structure part and a needle tip; two ends of the cavity structure part are respectively connected with the substrate and the non-tip end of the needle tip; a waterproof layer is arranged on the outer surface of the needle head; and the waterproof layer is prepared from an anionic copolymer of methacrylic acid units. Compared with a traditional microneedle carrying medicine through a needle head or a needle tip, the microneedle provided by the invention has the advantages that the large-capacity cavity structure is used for carrying medicine, so that the medicine carrying capacity of the microneedle is improved; the waterproof layer is prepared on the surface of the needle head, so that direct contact between the microneedle and body fluid is effectively buffered, the moisture resistance of the microneedle is improved, the mechanical strength at the transdermal moment can be maintained, the problem that an existing microneedle is rapidly swelled and softened after meeting skin tissue fluid is solved, and the penetration rate is increased; comprising the high-drug-loading-capacity microneedle array can meet the delivery requirement of large-dose drugs.

The invention discloses application of a sialic acid modified nano preparation in preparation of a continuous low-dose drug delivery system, and belongs to the technical field of medicine, sialic acid is a sialic acid-cholesterol derivative, according to a continuous low-dose drug delivery scheme, the drug delivery concentration is 1 / 3-1 / 10 of the maximum tolerated dose, and the drug delivery concentration is 1 / 3-1 / 10 of the maximum tolerated dose. The sialic acid modified nano preparation is a sialic acid modified epirubicin liposome. Experiments prove that a continuous low-dose administration scheme of the sialic acid modified nano preparation can remarkably reduce liver and spleen accumulation, improve the targeting efficiency of a tumor site and maintain the blood concentration for a long time. The invention provides a solution for solving the problem that the curative effect of continuous low-dose administration of the PEGylated nano preparation is influenced by the anti-PEG antibody.

The invention provides a rescue room bedside interaction system for smart medical treatment, and relates to the technical field of physical sign data processing, and the system comprises a doctor's advice recording module which is used for recording doctor's advice, and the doctor's advice comprises a medication category, a single medication dosage and medication frequency; the medicament characteristic recording module is used for recording the efficacy and the side effect of each medicament; the real-time physical sign recording module is used for periodically monitoring the monitored physical sign value of the patient in real time; the physical sign prediction module is used for periodically predicting and acquiring predicted physical sign values of the patient based on the initial physical sign sequential sequence of the patient, the efficacy and the side effect of the medicament and the doctor's advice; and the physical sign early warning module is used for judging whether the physical sign development trend of the patient is normal or not according to the actual medication data, the monitored physical sign numerical value and the predicted physical sign numerical value. The system and the method have the advantages of higher pertinence and higher flexibility of physical sign monitoring.

The invention discloses a non-small cell lung cancer cis-platinum mild drug-resistant cell strain and application thereof. According to the invention, two cisplatin-resistant cell strains of NSCLC are constructed by adopting low-dose drug exposure and pulse type drug contact modes, so that the drug resistance progress of clinical patients can be better simulated. The construction time of the cell strain is 6 months, and the obtained drug resistance index is between 1.5 and 5. The method can be used for constructing a cell model for studying low-intensity drug resistance of cis-platinum, and providing detection of biomarkers related to drug resistance in the early stage of drug resistance occurrence and evaluation of signal channels. The method has good research prospect and application value for clinical multidrug resistance mechanism research, discovery of drug resistance targets and application evaluation of multidrug combined use.

The present invention provides a method and system for configuring non-whole-dose drugs, which relates to the technical field of drug configuration. The method includes: constructing a drug database for storing the solvent parameters of main drugs and the drug usage data of patient information; screening out target patient information and target drug usage data from the drug database according to query conditions, screening out target solvent parameters from the drug database through a scalar function and performing scalar calculation to obtain a solvent prompt text; displaying the target patient information, target drug usage data and solvent prompt text according to a set arrangement format, and printing the display result through a configured printer to output a drug configuration form. By embedding a scalar function in the query to calculate the solvent parameters and dispensing the drugs according to the generated solvent prompt text, the calculation amount of the dispensing personnel for the drug configuration dose is greatly reduced, the dispensing speed is improved, the occurrence of error events is reduced, the medication safety of patients is guaranteed, and the medical quality is improved.

The present invention relates to needleless devices for delivering therapeutic and / or prophylactic agents, such as solid doses of drugs, including vaccines. Needleless devices disclosed herein include novel structural arrangements as well as actuation and operation modes, bringing improved functionality and benefits to users and / or patients.